Alzheimer’s disease takes a long time to develop, which suggests that it may be possible to design drugs that work early in the disease process, to delay the start of symptoms. Over the past decade, researchers have been testing a number of such “disease-modifying” drugs that target the earliest biological changes in Alzheimer’s, reports the October 2007 issue of the Harvard Mental Health Letter.
A research team led by Dr. Paul Harch, Assistant Professor of Clinical Medicine at Louisiana State University Health Sciences Center New Orleans and Director of the LSU Hyperbaric Medicine Fellowship Program, has published findings that show hyperbaric oxygen therapy improved spatial learning and memory in a model of chronic traumatic brain injury.
Accentia Biopharmaceuticals announces that it met with the Food and Drug Administration (FDA) on September_26, 2007 for a scheduled pre-Investigational New Drug (pre-IND) meeting on Revimmune™. The FDA has indicated its support for Accentia to submit an IND for a pivotal Phase 3 randomized controlled, multi-center clinical trial of Revimmune, the company’s potential therapeutic for refractory, relapsing-remitting Multiple Sclerosis (MS).
University of California, Irvine scientists have discovered how to reverse the learning and memory problems inherent in the most common form of mental impairment.
There have been improvements in cancer survival in Northern Ireland between 1993 and 2004, according to a new report from the Northern Ireland Cancer Registry (NICR).
India and the United States agreed to enhance cooperation in development of low-cost diagnostic and therapeutic medical technologies.
The PA Commission for Women turned the Point State Park Fountain bright pink, in observance of national Breast Cancer Awareness Month.
A multi-institution team led by USC faculty has received a five-year, $8.4 million grant from the National Institutes of Health for an ambitious effort to survey the genetic, physical and behavioral profiles of children with autism.
In people with chronic myeloid leukemia (CML), the drug Imatinib has been shown to drive cancer into remission, but the disease often returns when treatment is stopped. New research by UC Irvine scientists indicates that Imatinib could cure CML under certain circumstances if it is taken over a long enough period of time.
A Proclamation by George W. Bush, the President of the United States of America. He called upon Government officials, businesses, communities, health care professionals, educators, volunteers, and the people of the United States to continue Nation’s strong commitment to preventing, treating, and ultimately curing breast cancer.